DE19947010A1 - Das Gen PRV-1 und dessen Verwendung - Google Patents
Das Gen PRV-1 und dessen VerwendungInfo
- Publication number
- DE19947010A1 DE19947010A1 DE19947010A DE19947010A DE19947010A1 DE 19947010 A1 DE19947010 A1 DE 19947010A1 DE 19947010 A DE19947010 A DE 19947010A DE 19947010 A DE19947010 A DE 19947010A DE 19947010 A1 DE19947010 A1 DE 19947010A1
- Authority
- DE
- Germany
- Prior art keywords
- sequence
- prv
- polypeptide
- amino acids
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 title claims abstract description 70
- 102100024209 CD177 antigen Human genes 0.000 claims abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 24
- 108091033319 polynucleotide Proteins 0.000 claims description 22
- 102000040430 polynucleotide Human genes 0.000 claims description 22
- 239000002157 polynucleotide Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 11
- 208000037244 polycythemia vera Diseases 0.000 claims description 10
- 108020004511 Recombinant DNA Proteins 0.000 claims description 9
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010033661 Pancytopenia Diseases 0.000 claims description 4
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 42
- 108020004999 messenger RNA Proteins 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 240000006711 Pistacia vera Species 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 210000003714 granulocyte Anatomy 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 210000003013 erythroid precursor cell Anatomy 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 230000003394 haemopoietic effect Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018690 Granulocytosis Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- -1 secondary antibodies Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947010A DE19947010A1 (de) | 1999-09-30 | 1999-09-30 | Das Gen PRV-1 und dessen Verwendung |
| PCT/EP2000/009594 WO2001023554A1 (de) | 1999-09-30 | 2000-09-29 | Das gen prv-1 und dessen verwendung |
| CA002387702A CA2387702A1 (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
| BR0014444-4A BR0014444A (pt) | 1999-09-30 | 2000-09-29 | Gene prv-1 e uso do mesmo |
| EA200200286A EA200200286A1 (ru) | 1999-09-30 | 2000-09-29 | Ген prv-1 и его применение |
| EEP200200168A EE200200168A (et) | 1999-09-30 | 2000-09-29 | PRV-1-geen ja selle kasutamine |
| KR1020027004095A KR20020047191A (ko) | 1999-09-30 | 2000-09-29 | Ｐｒｖ-1 유전자 및 그의 용도 |
| MXPA02002800A MXPA02002800A (es) | 1999-09-30 | 2000-09-29 | El gen prv-1 y su uso. |
| EP00972665A EP1220920A1 (de) | 1999-09-30 | 2000-09-29 | Das gen prv-1 und dessen verwendung |
| PL00354184A PL354184A1 (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
| JP2001526936A JP2003510077A (ja) | 1999-09-30 | 2000-09-29 | Ｐｒｖ−１遺伝子とその使用 |
| AU11324/01A AU1132401A (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
| SK426-2002A SK4262002A3 (en) | 1999-09-30 | 2000-09-29 | The use of a peptide coded by the prv-1 gene or by a fragment thereof in production of a medicament acting as a growth factor |
| IL14877000A IL148770A0 (en) | 1999-09-30 | 2000-09-29 | The gene prv-1 and antibodies and pharmaceutical compositions for treating polycythemia vera |
| HU0203080A HUP0203080A2 (hu) | 1999-09-30 | 2000-09-29 | A PRV-1 gén és felhasználása |
| HR20020269A HRP20020269A2 (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
| CN00813580A CN1377408A (zh) | 1999-09-30 | 2000-09-29 | Prv－1基因及其应用 |
| CZ20021094A CZ20021094A3 (cs) | 1999-09-30 | 2000-09-29 | Pouľití polypeptidu kódovaného genem PRV-1 nebo jeho fragmentu pro výrobu léku působícího jako růstový faktor |
| ZA200202379A ZA200202379B (en) | 1999-09-30 | 2002-03-25 | The PRV-1 gene and use thereof. |
| NO20021498A NO20021498L (no) | 1999-09-30 | 2002-03-26 | Genet PRV-1 og anvendelsen av dette |
| BG106554A BG106554A (bg) | 1999-09-30 | 2002-03-27 | Ген prv-1 и неговото приложение |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947010A DE19947010A1 (de) | 1999-09-30 | 1999-09-30 | Das Gen PRV-1 und dessen Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19947010A1 true DE19947010A1 (de) | 2001-04-05 |
Family
ID=7923937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19947010A Withdrawn DE19947010A1 (de) | 1999-09-30 | 1999-09-30 | Das Gen PRV-1 und dessen Verwendung |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1220920A1 (et) |
| JP (1) | JP2003510077A (et) |
| KR (1) | KR20020047191A (et) |
| CN (1) | CN1377408A (et) |
| AU (1) | AU1132401A (et) |
| BG (1) | BG106554A (et) |
| BR (1) | BR0014444A (et) |
| CA (1) | CA2387702A1 (et) |
| CZ (1) | CZ20021094A3 (et) |
| DE (1) | DE19947010A1 (et) |
| EA (1) | EA200200286A1 (et) |
| EE (1) | EE200200168A (et) |
| HR (1) | HRP20020269A2 (et) |
| HU (1) | HUP0203080A2 (et) |
| IL (1) | IL148770A0 (et) |
| MX (1) | MXPA02002800A (et) |
| NO (1) | NO20021498L (et) |
| PL (1) | PL354184A1 (et) |
| SK (1) | SK4262002A3 (et) |
| WO (1) | WO2001023554A1 (et) |
| ZA (1) | ZA200202379B (et) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158599A0 (en) * | 2003-10-26 | 2004-05-12 | Yeda Res & Dev | Methods of modulating hematopoiesis |
| EP3594239B1 (en) | 2012-05-21 | 2024-10-30 | F. Hoffmann-La Roche AG | Methods for improving safety of blood-brain barrier transport |
| EP3638774B1 (en) * | 2017-06-14 | 2024-08-07 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0991757A1 (en) * | 1997-05-06 | 2000-04-12 | ZymoGenetics | Novel tumor antigens |
| IL139686A0 (en) * | 1998-06-02 | 2002-02-10 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DE19849044A1 (de) * | 1998-10-23 | 2000-04-27 | Univ Ludwigs Albert | Das Gen PRV-1 und dessen Verwendung |
| EP1141285A2 (en) * | 1998-12-16 | 2001-10-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
1999
- 1999-09-30 DE DE19947010A patent/DE19947010A1/de not_active Withdrawn
-
2000
- 2000-09-29 JP JP2001526936A patent/JP2003510077A/ja active Pending
- 2000-09-29 WO PCT/EP2000/009594 patent/WO2001023554A1/de not_active Ceased
- 2000-09-29 AU AU11324/01A patent/AU1132401A/en not_active Abandoned
- 2000-09-29 HR HR20020269A patent/HRP20020269A2/hr not_active Application Discontinuation
- 2000-09-29 BR BR0014444-4A patent/BR0014444A/pt not_active Application Discontinuation
- 2000-09-29 EP EP00972665A patent/EP1220920A1/de not_active Withdrawn
- 2000-09-29 MX MXPA02002800A patent/MXPA02002800A/es unknown
- 2000-09-29 CZ CZ20021094A patent/CZ20021094A3/cs unknown
- 2000-09-29 CA CA002387702A patent/CA2387702A1/en not_active Abandoned
- 2000-09-29 EE EEP200200168A patent/EE200200168A/et unknown
- 2000-09-29 KR KR1020027004095A patent/KR20020047191A/ko not_active Withdrawn
- 2000-09-29 SK SK426-2002A patent/SK4262002A3/sk unknown
- 2000-09-29 IL IL14877000A patent/IL148770A0/xx unknown
- 2000-09-29 PL PL00354184A patent/PL354184A1/xx not_active IP Right Cessation
- 2000-09-29 HU HU0203080A patent/HUP0203080A2/hu unknown
- 2000-09-29 CN CN00813580A patent/CN1377408A/zh active Pending
- 2000-09-29 EA EA200200286A patent/EA200200286A1/ru unknown
-
2002
- 2002-03-25 ZA ZA200202379A patent/ZA200202379B/en unknown
- 2002-03-26 NO NO20021498A patent/NO20021498L/no not_active Application Discontinuation
- 2002-03-27 BG BG106554A patent/BG106554A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1377408A (zh) | 2002-10-30 |
| IL148770A0 (en) | 2002-09-12 |
| ZA200202379B (en) | 2003-10-29 |
| PL354184A1 (en) | 2003-12-29 |
| BR0014444A (pt) | 2002-06-11 |
| HRP20020269A2 (en) | 2003-06-30 |
| SK4262002A3 (en) | 2002-09-10 |
| HUP0203080A2 (hu) | 2002-12-28 |
| AU1132401A (en) | 2001-04-30 |
| BG106554A (bg) | 2003-01-31 |
| WO2001023554A1 (de) | 2001-04-05 |
| MXPA02002800A (es) | 2002-07-22 |
| NO20021498D0 (no) | 2002-03-26 |
| EE200200168A (et) | 2003-04-15 |
| JP2003510077A (ja) | 2003-03-18 |
| CA2387702A1 (en) | 2001-04-05 |
| CZ20021094A3 (cs) | 2002-06-12 |
| EP1220920A1 (de) | 2002-07-10 |
| NO20021498L (no) | 2002-05-23 |
| KR20020047191A (ko) | 2002-06-21 |
| EA200200286A1 (ru) | 2002-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69017753T2 (de) | Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper. | |
| DE69636752T2 (de) | Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen | |
| EP0409113B1 (de) | Muteine des menschlichen Erythropoetins, ihre Herstellung und ihre Verwendung | |
| DE69519454T2 (de) | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen | |
| EP0538300B1 (de) | O-glycosyliertes ifn-alpha | |
| DE69434428T2 (de) | Neue Polypeptide und diese codierende DNAs | |
| DE69314754T2 (de) | Vorläufer B-Zelle stimulierender Faktor | |
| DE69635675T2 (de) | Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor | |
| DE69132814T2 (de) | Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5 | |
| DE69934239T2 (de) | Ly6h-gen | |
| DE69712124T2 (de) | Hormones de croissance humaines mutantes et leur utilisation | |
| DE69132813T2 (de) | Genetisches igfbp-5 rodierendes material | |
| DE69024693T2 (de) | Gene, die ein Protein mit menschlicher MACIF-Aktivität kodieren, Expressionsvektoren mit diesen Genen, Transformantenzellen und Proteine mit menschlicher MACIF-Aktivität | |
| DE69434997T2 (de) | Menschliches Chondromodulin-I-Protein | |
| DE69705017T2 (de) | Medikamente bindendes Protein | |
| DE69131979T2 (de) | Genetisches igfbp-4 rodierendes material | |
| DE69233155T2 (de) | Insulinartigen wachstumsfaktor bindendes protein | |
| EP0805204B1 (de) | Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung | |
| DE69132682T2 (de) | Zellwachstumsinhibitoren | |
| EP1123392B1 (de) | Das gen prv-1 und dessen verwendung | |
| DE69931345T2 (de) | Gen, welches für neues transmembranprotein kodiert | |
| EP0440321B1 (de) | Epididymis-spezifische Polypeptide und deren Verwendung | |
| DE3884853T2 (de) | Angiogenininhibitoren. | |
| DE19947010A1 (de) | Das Gen PRV-1 und dessen Verwendung | |
| EP1191035A2 (de) | Drei Mitglieder der Zytokinrezeptorfamilie Klasse II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |